Alex Gorsky assumed his current position as Chairman and CEO of Johnson & Johnson in 2012. He is the ninth leader of Johnson & Johnson since it was founded in 1886. Learn more about Alex and our leadership team.
In 2017, Johnson & Johnson opened the doors to Our Story at the Power House, a state-of-the-art physical exhibition at our world headquarters. The company also launched an interactive museum—ourstory.jnj.com— that celebrates over 130 years of innovations that have changed the course of human health.
Johnson & Johnson’s consumer brands are often the first and most personal experience people have with our company. Our baby care, beauty, oral care, self-care, women’s health and wound care brands have been trusted by consumers and healthcare professionals for more than 100 years.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we’re creating a future where disease is a thing of the past. We work tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.
With its Phase 3 clinical trial now fully enrolled, the Global Head of Research & Development at Janssen brings us up to speed on the progress of the company's vaccine candidate, including upcoming key milestones.